Intervention Review

Terazosin for benign prostatic hyperplasia

  1. Timothy J Wilt1,*,
  2. R William Howe2,
  3. Indy Rutks3,
  4. Roderick MacDonald1

Editorial Group: Cochrane Prostatic Diseases and Urologic Cancers Group

Published Online: 7 SEP 2011

Assessed as up-to-date: 13 SEP 1999

DOI: 10.1002/14651858.CD003851.pub2


How to Cite

Wilt TJ, Howe RW, Rutks I, MacDonald R. Terazosin for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD003851. DOI: 10.1002/14651858.CD003851.pub2.

Author Information

  1. 1

    VAMC, General Internal Medicine (111-0), Minneapolis, Minnesota, USA

  2. 2

    Lostwithiel Medical Practice, Lostwithiel, Cornwall, UK

  3. 3

    VAMC, Department of Internal Medicine (111-0), Minneapolis, Minnesota, USA

*Timothy J Wilt, General Internal Medicine (111-0), VAMC, One Veterans Drive, Minneapolis, Minnesota, 55417, USA. Tim.Wilt@med.va.gov.

Publication History

  1. Publication Status: Withdrawn from publication for reasons stated in the review
  2. Published Online: 7 SEP 2011

SEARCH

  1. Current Version

    Terazosin for benign prostatic hyperplasia

    Timothy J Wilt, R William Howe, Indy Rutks and Roderick MacDonald

    Article first published online: 7 SEP 2011 | DOI: 10.1002/14651858.CD003851.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Terazosin for benign prostatic hyperplasia

    Timothy Wilt, R William Howe, Indy Rutks and Roderick MacDonald

    Article first published online: 24 JAN 2000 | DOI: 10.1002/14651858.CD003851